C G Roehrborn

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. doi Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, J8 148, Dallas, Texas 75390 9110, USA
    J Urol 187:1732-8. 2012
  2. ncbi Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas Electronic address
    J Urol 191:1045-50. 2014
  3. doi The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study
    Claus G Roehrborn
    University of Texas Southwestern Medical Center, Dallas, Texas Scott and White Healthcare, Temple, Texas Western Urological Clinic, Salt Lake City, Utah Carolina Urological Research Center, Myrtle Beach, South Carolina Cosmetic Surgery Hospital, Brampton, and Oakville Trafalgar Memorial Hospital, Oakville, Ontario, Canada The Austin Hospital, Melbourne, Victoria, Australia, Urology Associates of Denver, Denver, Colorado Atlantic Urological Associates, Daytona Beach, and Pinellas Urology, St Petersburg, Florida Northwestern University and Southern Illinois University, Springfield, Illinois Weill Cornell Medical Center, New York, New York Urology Associates of Silicon Valley, San Jose, and SD Uro Research, San Diego, California Port Macquarie Hospital, Port Macquarie, and Figtree Private Hospital, Figtree, New South Wales, Australia Chesapeake Urology, Baltimore, Maryland Freedman, MD, Ltd, Las Vegas
    J Urol 190:2161-7. 2013
  4. ncbi Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies
    C G Roehrborn
    Departments of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    BJU Int 92:257-61. 2003
  5. doi Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial
    Claus G Roehrborn
    Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA
    Eur Urol 59:244-9. 2011
  6. doi Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern, Medical Center at Dallas, Texas 75390 9110, USA
    Urology 72:1061-7; discussion 1067. 2008
  7. ncbi The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia
    C G Roehrborn
    Department of Urology, UT Southwestern Medical Center, Dallas, Texas, USA
    BJU Int 93:21-6. 2004
  8. doi Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)
    Claus G Roehrborn
    Department of Urology, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, J8 142, Dallas, TX 75390 9110, USA
    Med Clin North Am 95:87-100. 2011
  9. ncbi Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia
    Claus G Roehrborn
    The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9100, USA
    J Urol 171:1194-8. 2004
  10. ncbi Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate
    C G Roehrborn
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, 75392 9110, USA
    Prostate Cancer Prostatic Dis 9:121-5. 2006

Research Grants

Detail Information

Publications109 found, 100 shown here

  1. doi Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, J8 148, Dallas, Texas 75390 9110, USA
    J Urol 187:1732-8. 2012
    ..We quantified the magnitude of symptom improvement required to achieve different levels of patient reported satisfaction, as assessed by the Patient Perception of Study Medication questionnaire...
  2. ncbi Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas Electronic address
    J Urol 191:1045-50. 2014
    ....
  3. doi The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study
    Claus G Roehrborn
    University of Texas Southwestern Medical Center, Dallas, Texas Scott and White Healthcare, Temple, Texas Western Urological Clinic, Salt Lake City, Utah Carolina Urological Research Center, Myrtle Beach, South Carolina Cosmetic Surgery Hospital, Brampton, and Oakville Trafalgar Memorial Hospital, Oakville, Ontario, Canada The Austin Hospital, Melbourne, Victoria, Australia, Urology Associates of Denver, Denver, Colorado Atlantic Urological Associates, Daytona Beach, and Pinellas Urology, St Petersburg, Florida Northwestern University and Southern Illinois University, Springfield, Illinois Weill Cornell Medical Center, New York, New York Urology Associates of Silicon Valley, San Jose, and SD Uro Research, San Diego, California Port Macquarie Hospital, Port Macquarie, and Figtree Private Hospital, Figtree, New South Wales, Australia Chesapeake Urology, Baltimore, Maryland Freedman, MD, Ltd, Las Vegas
    J Urol 190:2161-7. 2013
    ..We report the first multicenter randomized blinded trial of the prostatic urethral lift for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia...
  4. ncbi Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies
    C G Roehrborn
    Departments of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    BJU Int 92:257-61. 2003
    ....
  5. doi Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial
    Claus G Roehrborn
    Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA
    Eur Urol 59:244-9. 2011
    ..A 23% relative risk reduction (RRR) in prostate cancer (PCa) was shown in men receiving dutasteride in the 4-yr Reduction by Dutasteride of Prostate Cancer Events study, in whom biopsies were protocol dependent...
  6. doi Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern, Medical Center at Dallas, Texas 75390 9110, USA
    Urology 72:1061-7; discussion 1067. 2008
    ..To evaluate the efficacy of tolterodine extended release (ER), tamsulosin, and tolterodine ER plus tamsulosin in men with symptoms of overactive bladder and benign prostatic hyperplasia stratified by prostate-specific antigen (PSA) level...
  7. ncbi The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia
    C G Roehrborn
    Department of Urology, UT Southwestern Medical Center, Dallas, Texas, USA
    BJU Int 93:21-6. 2004
  8. doi Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)
    Claus G Roehrborn
    Department of Urology, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, J8 142, Dallas, TX 75390 9110, USA
    Med Clin North Am 95:87-100. 2011
    ..Perhaps as many as 30% of patients fail to achieve sufficient symptom improvement with medication, lifestyle adjustment, and fluid management, and may require more invasive or surgical treatment options...
  9. ncbi Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia
    Claus G Roehrborn
    The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9100, USA
    J Urol 171:1194-8. 2004
    ..We determined the effect of long-term treatment with finasteride on the incidence of acute urinary retention (AUR) and benign prostatic hyperplasia (BPH) related surgery in men with BPH...
  10. ncbi Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate
    C G Roehrborn
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, 75392 9110, USA
    Prostate Cancer Prostatic Dis 9:121-5. 2006
    ..If alfuzosin-induced apoptosis in prostate tissue, it was not evident by a measurable change in prostate volume after 3 months' treatment. Further analysis at 1 and 2 years will determine the effect of longer-term treatment...
  11. ncbi Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners
    C G Roehrborn
    Department of Urology, UT Southwestern Medical Center at Dallas, TX 75390 9110, USA
    Prostate Cancer Prostatic Dis 9:30-4. 2006
    ..These findings confirm that LUTS and EP are prevalent in the US population, affecting both patient and spouse, and may help in developing management strategies for EP...
  12. ncbi Definition of at-risk patients: baseline variables
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    BJU Int 97:7-11; discussion 21-2. 2006
    ..Further research is needed to clarify the role of chronic inflammation in the process of BPH progression...
  13. ncbi Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    BJU Int 96:572-7. 2005
    ....
  14. doi The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study
    Claus G Roehrborn
    Department of Urology, UT Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Eur Urol 57:123-31. 2010
    ....
  15. doi The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT stu
    Claus G Roehrborn
    Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390 9110, USA
    Eur Urol 55:461-71. 2009
    ..Knowledge of baseline factors that influence outcomes for men with benign prostatic hyperplasia (BPH) receiving medical therapy may help to improve outcomes and cost effectiveness...
  16. ncbi A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia
    Claus G Roehrborn
    University of Texas Southwestern Medical Center at Dallas, Department of Urology, 75390 9110, USA
    Eur Urol 48:445-52; discussion 452. 2005
    ..To determine the onset of improvement in benign prostatic hyperplasia symptoms in patients after treatment with doxazosin gastrointestinal therapeutic system (DOX GITS) versus placebo...
  17. doi The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia
    C G Roehrborn
    Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA
    Int J Impot Res 20:S19-26. 2008
    ..Lastly, serum PSA does not loose its usefulness as a cancer marker for prostate cancer even if certain medications reduce serum PSA values predictably by 50%...
  18. doi Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9110, USA
    J Urol 180:1228-34. 2008
    ..Preliminary data have suggested phosphodiesterase type 5 inhibitor efficacy in men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia...
  19. ncbi Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence
    Claus G Roehrborn
    The University of Texas Southwestern Medical Center, Dallas, TX 75390 911, USA
    BJU Int 97:1003-6. 2006
    ..They found that it significantly reduced incontinent episodes and improved patient perception of treatment benefit in men with an overactive bladder..
  20. doi BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE
    Claus G Roehrborn
    UT Southwestern Medical Center at Dallas, Dallas, TX 75390 9110, USA
    BJU Int 101:17-21. 2008
    ....
  21. ncbi Is there a place for combination medical therapy?
    C G Roehrborn
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Curr Opin Urol 11:17-25. 2001
    ..A trial addressing this specific patient population, in whom theoretically the most benefit might be gained from combining both classes of drugs to address symptoms and prevent outcomes, would be a welcome addition to our knowledge base...
  22. doi The economic burden of prostate cancer
    Claus G Roehrborn
    Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390 9110, USA
    BJU Int 108:806-13. 2011
    ..Unless new strategies are devised to increase the efficiency of healthcare provision, the economic burden of prostate cancer will continue to rise...
  23. pmc Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
    Claus G Roehrborn
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    Clin Interv Aging 3:511-24. 2008
    ..The long-term clinical efficacy and good cardiovascular and sexual function safety profile of alfuzosin can contribute to an improved quality of life for aging men with LUTS/BPH...
  24. ncbi Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker
    C G Roehrborn
    Department of Urology, The University of Texas Southwestern Medical Center at Dallas, 75390 9110, USA
    Urology 58:55-63; discussion 63-4. 2001
    ..The most frequently reported adverse event potentially related to alpha blockade was dizziness, which occurred in 5.0% of patients treated with 10 mg alfuzosin compared with 2.1% of patients given placebo...
  25. doi Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9110, USA
    Eur Urol 55:472-9. 2009
    ..Some men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB) symptoms may benefit from antimuscarinic therapy, with or without an alpha-adrenergic antagonist...
  26. ncbi Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes
    Claus G Roehrborn
    Department of Urology, The University of Texas Southwestern Medical Center at Dallas, 75390 9110, USA
    Eur Urol 42:1-6. 2002
    ..To assess the utility of voiding and filling symptom subscores in predicting features of benign prostatic hyperplasia (BPH) progression, including acute urinary retention (AUR) and prostate surgery...
  27. doi Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Urology 78:641-6. 2011
    ....
  28. doi Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulo
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
    BJU Int 107:946-54. 2011
    ....
  29. ncbi Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men
    C G Roehrborn
    Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
    Prostate Cancer Prostatic Dis 9:432-8. 2006
    ..Therefore, dutasteride demonstrated similar efficacy and safety profiles in African-Americans and Caucasians...
  30. doi Pathology of benign prostatic hyperplasia
    C G Roehrborn
    Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390 9110, USA
    Int J Impot Res 20:S11-8. 2008
    ..Recognizing the different entities and determining their presence in individual patients may help with therapeutic decision making...
  31. doi Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients
    Amit Gupta
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Eur Urol 55:1124-33. 2009
    ..This axis is involved in cell proliferation, angiogenesis, extracellular matrix degradation, invasion, and metastases...
  32. ncbi Interexaminer reliability of transrectal ultrasound for estimating prostate volume
    S Sech
    Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
    J Urol 166:125-9. 2001
    ..Reliability in patients without prostate cancer appears to be better for larger volume prostates and for examiners with more experience...
  33. doi Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence
    Robert S Svatek
    Department of Urology, University of Texas Southwestern Medical Centre, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Prostate 69:886-94. 2009
    ..We tested the ability of several pre-operative blood-based biomarkers to enhance the accuracy of standard post-operative features for the prediction of biochemical recurrence (BCR) after radical prostatectomy (RP)...
  34. ncbi The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
    John D McConnell
    University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    N Engl J Med 349:2387-98. 2003
    ..The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown...
  35. ncbi Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial
    Steven A Kaplan
    Department of Urology, Weill Cornell Medical College, New York, NY 10021, USA
    JAMA 296:2319-28. 2006
    ..Men with overactive bladder and other lower urinary tract symptoms may not respond to monotherapy with antimuscarinic agents or alpha-receptor antagonists...
  36. doi Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer
    Jose A Karam
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Clin Cancer Res 14:1418-22. 2008
    ..The aim of the study was to evaluate whether preoperative plasma endoglin improves the prediction of lymph node metastases in patients with clinically localized prostate cancer...
  37. ncbi Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience
    Stanley L Liauw
    Department of Radiation Oncology, University of Texas Southwestern Medical Center at Dallas, 75390 9110, USA
    Urology 61:1204-10. 2003
    ....
  38. ncbi Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9110, USA
    Urology 63:709-15. 2004
    ..To assess the long-term safety and efficacy of dutasteride, a dual type 1 and type 2 5-alpha-reductase inhibitor, in the treatment of symptomatic benign prostatic hyperplasia and associated lower urinary tract symptoms...
  39. ncbi Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials
    C G Roehrborn
    University of Texas Southwestern Medical Center, Dallas, Texas 75390-9110, USA
    Urology 58:210-6. 2001
    ....
  40. ncbi Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial
    C G Roehrborn
    Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
    Urology 58:953-9. 2001
    ..It is well tolerated from a cardiovascular viewpoint and is not associated with abnormal ejaculation...
  41. doi Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score
    Steven A Kaplan
    Department of Urology, Weill Cornell Medical College, New York, NY 10021, USA
    BJU Int 102:1133-9. 2008
    ....
  42. ncbi Reporting of acute urinary retention in BPH treatment trials: importance of patient follow-up after discontinuation and case definitions
    Claus G Roehrborn
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Urology 59:811-5. 2002
    ..Because of differences in study designs, the present analysis was undertaken to compare data on the rates of AUR across different BPH trials accurately...
  43. ncbi The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Urol 179:616-21; discussion 621. 2008
    ..We report preplanned 2-year analyses...
  44. ncbi Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial
    M I Resnick
    Department of Urology, Case Medical Center, Cleveland, OH 44106, USA
    Prostate Cancer Prostatic Dis 10:155-9. 2007
    ..07 versus placebo) and day 29 (P=0.003 versus placebo). Alfuzosin 10 mg once daily exhibits a rapid onset of action, with improvements in Q(max) and LUTS maintained through 1 month of treatment...
  45. ncbi Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence
    Jose A Karam
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    Prostate 67:614-22. 2007
    ....
  46. doi Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer
    Amit Gupta
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Clin Cancer Res 14:7385-90. 2008
    ..We assessed whether preoperative plasma levels of HGF can enhance the accuracy of standard models for predicting pathologic features and clinical outcomes...
  47. ncbi Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts
    Bahaa S Malaeb
    Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA
    Urol Oncol 25:291-7. 2007
    ..To evaluate the feasibility of radical retropubic prostatectomy (RRP) as an option for treating men older than 70 years with organ confined prostate cancer and to compare biochemical progression-free survival with younger cohorts...
  48. ncbi Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9110, USA
    Urology 60:434-41. 2002
    ..To study the efficacy and safety of dutasteride, a dual inhibitor of the 5-alpha-reductase isoenzymes types I and II...
  49. ncbi Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia
    Steven A Kaplan
    Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York 10021, USA
    Urology 68:328-32. 2006
    ..To evaluate the efficacy and safety of nighttime dosing with tolterodine extended release (TER) in men with overactive bladder (OAB) and nocturia...
  50. ncbi Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    JAMA 291:1325-32. 2004
    ..Salvage radiotherapy may potentially cure patients with disease recurrence after radical prostatectomy, but previous evidence has suggested that it is ineffective in patients at the highest risk of metastatic disease progression...
  51. ncbi Verification and incorporation biases in studies assessing screening tests: prostate-specific antigen as an example
    Amit Gupta
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Urology 64:106-11. 2004
    ..We have reviewed how these biases have influenced such studies...
  52. ncbi Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    J Urol 174:2046-50. 2005
    ..We assessed the differential expression of survivin and other apoptotic markers in stromal and epithelial compartments of benign prostatic hyperplasia (BPH) and normal prostate tissue...
  53. ncbi Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma
    Robert S Svatek
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Urol 179:478-84; discussion 484. 2008
    ..We tested the hypothesis that urinary cathepsin B and L are associated with bladder cancer recurrence and invasiveness in patients with a history of nonmuscle invasive urothelial carcinoma of the bladder...
  54. ncbi The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response
    Leonard S Marks
    Department of Urology, University of California, Los Angeles School of Medicine and Urological Sciences Research Foundation, Los Angeles, California 90232, USA
    J Urol 177:1408-13. 2007
    ..We determined the effects of dutasteride on transition and peripheral zone volume, and the clinical value of the transition zone index in men with benign prostatic hyperplasia...
  55. ncbi A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer
    Edouard J Trabulsi
    Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Urology 72:1298-302; discussion 1302-4. 2008
    ..We studied a group of patients undergoing ART by comparing them with a matched control group undergoing SRT after biochemical failure...
  56. ncbi Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia
    Kevin M Slawin
    Baylor Prostate Center, Scott Department of Urology, Baylor College of Medicine, Methodist Hospital, Houston, Texas, USA
    Urology 67:84-8. 2006
    ....
  57. ncbi Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy
    Jose A Karam
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Lancet Oncol 8:128-36. 2007
    ....
  58. doi Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy
    Robert S Svatek
    Department of Urology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9110, USA
    Clin Cancer Res 14:3362-6. 2008
    ..The aim of this study was to evaluate the association of preoperative plasma endoglin levels with established clinical and pathologic features of prostate cancer and disease progression after radical prostatectomy...
  59. ncbi Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans
    Amit Gupta
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Urology 68:1198-205. 2006
    ..We investigated the associations of BPH with anthropometric and metabolic parameters in this prospective study of Vietnam War veterans...
  60. ncbi Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design
    Paul Siami
    Department of Urology, Welborn Clinic, Evansville, IN 47714, USA
    Contemp Clin Trials 28:770-9. 2007
    ..5 ng/mL. A total of 4838 subjects have been enrolled. This paper describes the rationale, design and baseline data of the CombAT study...
  61. ncbi Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study
    Claus G Roehrborn
    University of Texas, Southwestern Medical Center, Dallas, TX, USA
    BJU Int 97:734-41. 2006
    ..To evaluate the effect of alfuzosin 10 mg once daily administered for 2 years on progression events in men with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH)...
  62. ncbi Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia
    Claus G Roehrborn
    University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Urology 62:894-9. 2003
    ..To examine the effect of finasteride on serum testosterone in men with benign prostatic hyperplasia (BPH)...
  63. ncbi Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy
    Seyed M Khoddami
    Department of Urology, The University of Texas South Western Medical Center, Dallas, USA
    BJU Int 94:42-6. 2004
    ..To examine whether Gleason score (GS) 3 + 4 and 4 + 3 cancers at radical prostatectomy behave differently and whether this behaviour is independently associated with prostate cancer outcome...
  64. ncbi Acute relief or future prevention: is urology ready for preventive health care?
    C G Roehrborn
    The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
    Urology 56:12-9. 2000
    ..This signals an important reorientation of clinical investigation in BPH...
  65. ncbi Accurate determination of prostate size via digital rectal examination and transrectal ultrasound
    C G Roehrborn
    University of Texas Southwestern Medical Center, Section of Urology, VA North Texas Health Care System, Dallas 75232, USA
    Urology 51:19-22. 1998
    ..Because of these results, a prospective study is currently in progress to develop models or visual aids to assist physicians in more accurately predicting a threshold prostate volume via DRE...
  66. pmc Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH
    C G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9910, USA
    Prostate Cancer Prostatic Dis 14:143-8. 2011
    ..75 times those for RE- patients (P=0.0127). Absence of seminal emission may predict superior treatment efficacy of silodosin in individual patients...
  67. doi The effect of the approach to radical prostatectomy on the profitability of hospitals and surgeons
    Yair Lotan
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
    BJU Int 105:1531-5. 2010
    ....
  68. doi Herbal/hormonal dietary supplement possibly associated with prostate cancer progression
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    Clin Cancer Res 14:607-11. 2008
    ..After two men developed an unusual course of clinically aggressive prostate cancer within months of starting daily consumption of the same HHDS product, we investigated the effect of this product on prostate cancer progression...
  69. ncbi Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9110, USA
    Clin Cancer Res 13:5377-84. 2007
    ..We tested the hypothesis that plasma levels of HER2 and/or EGFR are associated with prostate cancer stage and prognosis in patients with clinically localized disease...
  70. doi Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    J Urol 179:1593-7. 2008
    ....
  71. ncbi Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    BJU Int 101:232-7. 2008
    ....
  72. ncbi Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes
    Yair Lotan
    Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9110, USA
    J Clin Oncol 23:1911-20. 2005
    ..To assess the estimated effect of finasteride prevention of prostate cancer on overall survival...
  73. ncbi Idiopathic scrotal elephantiasis
    Brad J Hornberger
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Urology 65:389. 2005
    ..We present a unique case of a 22-year-old man with idiopathic lymphedema isolated to the scrotum. After acquired causes of lymphedema were ruled out, the patient was treated with scrotectomy and scrotal reconstruction...
  74. ncbi Alpha(2) macroglobulin, a PSA binding protein, is expressed in human prostate stroma
    Victor K Lin
    Department of Urology, The University of Texas, Southwestern Medical Center, Dallas, Texas, USA
    Prostate 63:299-308. 2005
    ..It also plays roles in molecular trapping and targeting. In this study, we characterized alpha(2)-M expression in the human prostate...
  75. ncbi The value of your time: evaluation of effects of changes in medicare reimbursement rates on the practice of urology
    Yair Lotan
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    J Urol 172:1958-62. 2004
    ..We studied the effect of these changes on hourly reimbursement rates for various services provided by urologists...
  76. ncbi The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate
    Elie A Benaim
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Prostate 60:310-6. 2004
    ..This study was designed to determine whether androgen ablation (AA) affects expression of alpha1A-adrenergic receptors (AR) in the human prostate...
  77. pmc Serum dioxin, testosterone, and subsequent risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans
    Amit Gupta
    The University of Texas School of Public Health, Regional Campus at Dallas, Dallas, Texas 75390 9110, USA
    Environ Health Perspect 114:1649-54. 2006
    ..It has been hypothesized that dioxins may be partially responsible for an increase of male reproductive tract disorders such as testicular cancer, cryptorchidism, and hypospadias...
  78. ncbi The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy
    Yair Lotan
    Departments of Urology and Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9110, USA
    J Urol 171:2209-14. 2004
    ..We examined if the percent of positive biopsies is associated with features of biologically aggressive prostate cancer, biochemical progression and development of distant metastases in patients undergoing radical prostatectomy (RP)...
  79. doi Development of a highly accurate nomogram for prediction of the need for exploration in patients with renal trauma
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Trauma 64:1451-8. 2008
    ..To develop and validate a nomogram for predicting the need for renal exploration after renal trauma...
  80. ncbi Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis
    Shahrokh F Shariat
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    J Clin Oncol 25:349-55. 2007
    ..To assess whether preoperative plasma levels of urokinase-type plasminogen activator (uPA) and its soluble receptor (uPAR) would predict cancer of the prostate (CaP) presence, stage, and prognosis...
  81. ncbi Contemporary laparoscopic and open radical retropubic prostatectomy: pathologic outcomes and Kattan postoperative nomograms are equivalent
    Sangtae Park
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Urology 69:118-22. 2007
    ....
  82. ncbi Survivin expression is associated with features of biologically aggressive prostate carcinoma
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 91120, USA
    Cancer 100:751-7. 2004
    ....
  83. ncbi Evidence-based validation of the predictive value of the American Association for the Surgery of Trauma kidney injury scale
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Texas 75390 9110, USA
    J Trauma 62:933-9. 2007
    ..To evaluate the predictive value of the American Association for the Surgery of Trauma (AAST) kidney injury scale for the management of traumatic renal injuries...
  84. ncbi Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    J Urol 178:1229-36; discussion 1236-7. 2007
    ....
  85. ncbi Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder
    Shahrokh F Shariat
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    J Urol 173:1518-25. 2005
    ..We developed and validated nomograms that accurately predict disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma (TCC) of the bladder using a large international cohort...
  86. doi Use of electronic medical records to identify patients at risk for prostate cancer in an academic institution
    L Erickstad
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
    Prostate Cancer Prostatic Dis 14:85-9. 2011
    ..53 ng ml(-1) per year. EMR allows identification of patients at increased risk of prostate cancer who are not evaluated. Prospective studies are needed to identify ways to improve appropriate evaluation and detection of prostate cancer...
  87. ncbi Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians
    Y Lotan
    Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Texas 75390 9110, USA
    Prostate Cancer Prostatic Dis 5:111-4. 2002
    ..These findings suggest that the rate of metabolism of PSA is similar for these groups. Further studies are needed to explain racial differences of serum PSA in patients with and without prostate cancer...
  88. ncbi Gleason score predicts androgen independent progression after androgen deprivation therapy
    E A Benaim
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    Eur Urol 42:12-7. 2002
    ..In this study, we evaluated the prognostic value of the Gleason grading system in predicting progression to androgen independent prostate cancer (AIPC)...
  89. ncbi Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination
    C G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9110, USA
    Urology 57:1087-92. 2001
    ..Although the DRE estimates generally tend to underestimate the TRUS-measured prostate volume, these tools may be useful in identifying men with enlarged prostate glands...
  90. ncbi Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group
    C G Roehrborn
    The University of Texas Southwestern Medical Center, Dallas, TX 07525 9110, USA
    Eur Urol 37:528-36. 2000
    ....
  91. doi First-year costs of treating prostate cancer: estimates from SEER-Medicare data
    C G Roehrborn
    Department of Urology, UT Southwestern Medical Center at Dallas, Dallas, TX, USA
    Prostate Cancer Prostatic Dis 12:355-60. 2009
    ..Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13,091, prevention strategies have the potential to reduce health-care costs...
  92. ncbi Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis
    M S Pearle
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas 75235 9110, USA
    J Endourol 13:679-85. 1999
    ..To determine the efficacy of commonly used medications in comparison with placebo or no treatment for the prevention of renal stone recurrence (metaphylaxis) as documented in the literature...
  93. doi Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review
    S A Kaplan
    Department of Urology, Weill Cornell Medical College, Cornell University, New York, NY 10021, USA
    Int J Clin Pract 65:487-507. 2011
    ..Monitoring men for AUR is recommended, especially those at increased risk, and particularly within 30 days after starting antimuscarinic treatment...
  94. ncbi Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater
    Steven A Kaplan
    Columbia University Medical Center, New York, New York, USA
    J Urol 175:217-20; discussion 220-1. 2006
    ..We examined data from the Medical Therapy of Prostatic Symptoms trial to determine the relationship between baseline TPV and the effect of medical therapy in men with LUTS secondary to BPH...
  95. ncbi Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial
    J Curtis Nickel
    Department of Urology, Queen s University, Kingston General Hospital, Kingston, Ontario, Canada
    J Urol 178:896-900; discussion 900-1. 2007
    ..5 mg dutasteride daily decreases the risk of biopsy detectable prostate cancer. All men underwent biopsy before study entry, allowing review of the relationship between histological prostate inflammation and prostatitis symptoms...
  96. ncbi Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin
    Alberto Briganti
    Department of Urology, Vita Salute University San Raffaele, Milan, Italy
    BJU Int 100:528-32. 2007
    ..To test whether the rate of lymph node invasion (LNI) differs between patients treated with radical prostatectomy (RP) at a European or a North American centre...
  97. pmc Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy
    Andrew J Stephenson
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
    J Clin Oncol 25:2035-41. 2007
    ..We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence...
  98. ncbi Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling
    Robert Serfling
    Department of Mathematical Sciences, University of Texas at Dallas, Richardson, TX 75083, USA
    J Urol 177:2352-6. 2007
    ..By decreasing prostate volume 5alpha-reductase inhibitors may enhance cancer detection, which may explain the greater detection of high grade tumors in the finasteride arm of the Prostate Cancer Prevention Trial...
  99. ncbi Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium
    Felix K H Chun
    Department of Urology, University Medical Centre, Eppendorf, Hamburg, Germany
    Eur Urol 52:1067-74. 2007
    ..The contemporary ability of prostate-specific antigen (PSA) to predict pathologic stage in men with localized prostate cancer was recently questioned...
  100. ncbi First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia
    Leonard S Marks
    Urological Sciences Research Foundation and Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, California 90232, USA
    Urology 62:888-93. 2003
    ..Alfuzosin OD is an extended-release formulation of a uroselective, alpha1-adrenoreceptor-blocking agent (alpha-blocker) used in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia...
  101. doi Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer
    Andrea Gallina
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    BJU Int 101:1513-8. 2008
    ..To examine the stage migration patterns in patients treated with radical prostatectomy (RP) for prostate cancer in Europe and in the USA in the last 20 years...

Research Grants3

  1. Alternate Therapies for Benign Prostate Symptoms
    Claus Roehrborn; Fiscal Year: 2004
    ..8) Determine whether saw palmetto or pygeum africanum compared to placebo induce measurable changes in prostate volume, transition zone volume, serum PSA and other serum or tissue based biomarkers of BPH. ..
  2. Minimally Invasive Surgical Therapies Treatment Consort*
    Claus Roehrborn; Fiscal Year: 2005
    ..The MIST Study Group will be a blueprint for a technology assessment group applicable to other areas of urology and other medical or surgical subspecialties. ..